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Background: Pre-diabetes and non-alcoholic fatty liver disease (NAFLD) are associated with an unhealthy lifestyle
and pose extremely high costs to the healthcare system. In this study, we aim to explore whether individualized
aerobic exercise (AEx) and low carbohydrate diet (LCh) intervention affect hepatic fat content (HFC) in pre-diabetes
via modification of gut microbiota composition and other post-interventional effects.
Methods/design: A 6-month randomized intervention with 6-month follow-up is conducted from January 2013 to
December 2015. The target sample size for intervention is 200 postmenopausal women and middle-aged men aged
50–65 year-old with pre-diabetes and NAFLD. The qualified subjects are randomized into 4 groups with 50 subjects
in each group: 1 = AEx, 2 = LCh, 3 = AEx + LCh, and 4 = control. In addition, two age-matched reference groups
(5 = pre-diabetes without NAFLD (n = 50) and 6 = Healthy without pre-diabetes or NAFLD (n = 50)) are included. The
exercise program consists of progressive and variable aerobic exercise (intensity of 60 to 75% of initial fitness level,
3–5 times/week and 30–60 min/time). The diet program includes dietary consultation plus supplementation with a
special lunch meal (40% of total energy intake/day) which aims to reduce the amount of carbohydrate
consumption (30%). The control and reference groups are advised to maintain their habitual habits during the
intervention. The primary outcome measures are HFC, serum metabolomics and gut microbiota composition. The
secondary outcome measures include body composition and cytokines. In addition, socio-psychological aspects,
social support, physical activity and diet will be performed by means of questionnaire and interview.
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Discussion: Specific individualized exercise and diet intervention in this study offers a more efficient approach for
liver fat reduction and diabetes prevention via modification of gut microbiota composition. Besides, the study
explores the importance of incorporating fitness assessment and exercise in the management of patients with
pre-diabetes and fatty liver disorders. If our program is shown to be effective, it will open new strategies to combat
these chronic diseases.
Trial registration: Current Controlled Trials: ISRCTN42622771.
Keywords: Liver fat content, Glucose metabolism, Lipid metabolism, Gut microbiota, Metabonomics, Human,
Clinical settingBackground
Non-alcoholic fatty liver disease (NAFLD) is becoming the
most common cause of chronic liver disease in the devel-
oping world, and occurs in 17-30% of the population in
Western countries and 2-4% worldwide [1]. In China the
prevalence of NAFLD is 10-30% and up to 75% among
obese and type 2 diabetes (T2D) [2]. At the same time, the
prevalence of pre-diabetes has increased about 5-15% an-
nually in different parts of China [3-5]. The main causes
of pre-diabetes and NAFLD are related to lifestyle change
due to modernization and both of them are largely pre-
ventable by changing the lifestyle.
It has been known for decades that gut microbes play an
important role in metabolic, physiological and immuno-
logical processes in the human body [5-7]. Recently, studies
have shown that unbalanced gut microbiota composition,
i.e. dysbiosis, is associated with obesity-related metabolic
disorders [8], T2D [9] and cardiovascular diseases (CVDs)
[10] as well as longevity [11]. In addition, gut-derived bac-
terial components and metabolites are possible contribu-
tors to the onset of inflammation and further hepatic
insulin resistance (IR) since the liver gains a substantial
amount of nutrient- and metabolite-rich blood through
the portal vein which links it to gut [12]. Recent evidence
suggests a role for the gut microbiota both in the etiology
and progression of hepatic fat accumulation (HFA), which
is a multifactorial phenomenon associated with central
obesity and metabolic syndrome [13,14].
The gut bacteria affect an individual’s ability to utilize
energy from diet and when unbalanced microbiota com-
position can sustain a condition of subclinical chronic
activation of the immune system, or so called systemic
low-grade inflammation (SLGI), inducing insulin re-
sistance and enhancing the metabolic risk [15]. On the
other hand, in vivo studies show that some viruses
such as enteroviruses can affect the metabolic status by
directly infecting the liver and pancreas, while others
such as adenoviruses can induce SLGI by infecting
adipose tissue and interacting with mucosal immune
system [16-18].It is known that physical activity activates stomach and
bowel function by altering local circulation and affects in-
testinal mucosal immunity. Interestingly, recent animal
studies have shown that physical activity and diet cause
compositional changes in gut microbiota [19,20]. Another
study has shown that life-long calorie restriction of both
high-fat and low-fat diet, but not voluntary exercise, sig-
nificantly changed the overall structure of the gut micro-
biota of C57BL/6 J mice [11]. However, this study did not
detail the intensity and duration of the exercise. Thus the
effect of exercise on microbiota is still largely unknown.
The mechanism underlying the effects of exercise and
diet on gut microbiota needs to be established. Finally,
data from human studies, though sparse, suggests that
exercise can reduce liver fat [21] and thus the benefits
of exercise may be mediated, in part, by a reduction in
hepatic lipogenesis [22].
Objectives and hypothesis
The gut microbiota composition can be modified by exer-
cise and diet. Therefore, changes in the level of physical
activity and composition of diet may result in favourable
changes in microbiota composition which could, in
turn, be accompanied by reductions in liver fat content,
thus improving glucose and lipid metabolism and insulin
sensitivity. A six-month exercise and diet intervention
is enough to induce re-patterning of microbiota compos-
ition. However, “healthy” gut microbiota composition needs
persistent exercise and balanced diet. Subjects may relapse
to an “unhealthy” gut microbiota composition after cessa-
tion of exercise and balanced diet.
Therefore, the purpose of this study is to investigate
the gut microbiota composition of postmenopausal women
and middle aged men with pre-diabetic NAFLD compared
to healthy controls, and whether chronic but latent bacter-
ial infections are more frequent in NAFLD subjects than in
healthy subjects. In addition, we will determine whether
aerobic exercise and low carbohydrate diet reduce liver fat
content via modification of gut microbiota composition in
postmenopausal women and middle-aged men.
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Trial design
This is a six-arm study with four-arm randomized con-
trolled trial and an additional 2 arms as references (Figure 1).
Participants are recruited from the outpatient registration
pool of those who have participated in annual health
checks for diabetes and liver fat during 2012 to 2013 at
the Yangpu District Health Care Service Centres, Shanghai,
China. After an initial screening, potential subjects will
be assessed for inclusion in the run-in trial. Those
subjects who meet the inclusion criteria will be then
invited to the intervention and follow-up study for a
total duration of 1 year (6-month intervention and 6
month follow-up). Those participants who are quali-
fied for the intervention study will be randomized
into 4 groups after baseline assessments. Those subjects
who are qualified for the reference groups will not be
randomized.
Eligibility criteria
1. Inclusion criteria for intervention groups:
Men or women aged 50–65 years with fasting glucose
between 5.6 to 6.9 mmol/or glucose between 7.8 to
11.0 mmol/L 2 hour after the intake of glucose (75 g), di-
agnosed as NAFLD by 1H MRS (liver fat >5%) [23] and by
questionnaire that on-going or recent alcohol consump-
tion is <21 drinks on average per week in men and < 14
drinks on average per week in women [24]; no chronic
cardiovascular, serious musculoskeletal or gastrointestinalFigure 1 Design of the AELC-study.problems and not on extreme diets; and for women,
serum follicle-stimulating hormone level greater than
30 IU/L and last menstruation more than 6 months ago
but within 10 years.
2. Inclusion criteria for reference groups:
Reference group 1: Men or women aged 50–65years
with fasting glucose between 5.6 to 6.9 mmol/L or glucose
between 7.8 to 11.0 mmol/L 2 hours after intake of glu-
cose (75 g), not be diagnosed to have NAFLD by 1H MRS
(<5%), no chronic cardiovascular, serious musculoskeletal
or gastrointestinal problems and not on extreme diets;
and for women, serum follicle-stimulating hormone level
greater than 30 IU/L and last menstruation more than 6
months ago but within 10 years.
Reference group 2: Men or women aged 50–65 years
with fasting glucose below 5.6 mmol/L or glucose
below 7.8 mmol/L after 2 hour in takes of glucose
(75 g), no NAFLD by 1H MRS (<5%), no chronic car-
diovascular, serious musculoskeletal or gastrointestinal
problems and not on extreme diets; and for women,
serum follicle-stimulating hormone level greater than
30 IU/L and last menstruation more than 6 months
ago but within 10 years.
3. Exclusion criteria:
Body mass index (BMI) > 38 kg/m2; serious cardiovas-
cular or musculoskeletal problems; diagnosed Type 1
diabetes and T2D; and mental illness.
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The laboratory tests and interventions are performed
and managed at the Department of Sport Medicine,
Shanghai University of Sport, the Yangpu District Health
Care Service Centres and the Department of Endocrin-
ology, Shidong Hospital, and Clinical Nutrition Centre
at Fudan University Huadong Hospital, Shanghai, China.
Interventions
1. Exercise group:
Specific supervised individualized exercise (mainly aer-
obic exercise such as Nordic brisk walking + stretching
and other group exercise) programs will be developed by
an exercise researcher after baseline assessments on the
basis of each individual’s fitness level. The supervised exer-
cise program will be progressive and variable and will be
monitored by an exercise researcher during the course of
the study. The intensity and duration of exercise will be
increased from 60% to 75% of the maximum oxygen up-
take (estimated from fitness test) and from 30 to 60 min
per session, and the frequency from 3 to 5 times a week,
and will be updated monthly.
2. Diet group:
Dietary programmes are developed after baseline assess-
ments on the basis of each individual’s current dietary in-
takes and body weight. Overweight/obese participants are
advised to moderately reduce their total energy intake (by
300–500 kcal per day for the first 3 months) with guidance
on the proportion of macronutrients to be consumed. The
target is to reduce body weight by 3 kg in the first 3
months of the intervention. After this period, the partici-
pants are advised to maintain their achieved body weight
reduction, and continue to gradually reduce their body
weight towards normal levels, with a target of a 10%
reduction from their initial body weight. Participants
with normal weight are advised to maintain their body
weight.
During the intervention, each meal is planned by a
clinical nutritionist. We provide lunch daily to each par-
ticipant during the course of the intervention. The lunch
accounts for 40% of the total daily energy intake. The
breakfast and dinner each account for 30% of the total
daily energy intake. The proportion of macronutrients
are planned as 30-40% carbohydrate with < 5% sucrose
and with 18-20% as fiber, 40% fat (SAFA 10%, MUFA
15-20%, PUFA 10%) and 20% protein. The lunch will be
prepared under the guidance of a clinical nutritionist at
the Student Restaurant of Shanghai University of Sport.
Each meal will contain three to four dishes of foods
commonly eaten by Chinese families in Shanghai. Atrained study staff member will weigh each item for each
specific person according to the dietary plan and the
cooked dishes will be put into a named lunch box for
each participant. The lunch box will be then delivered to
the study district office where the study subjects are
gathered and the eating will be monitored. If the partici-
pants don’t have time to come to the lunch, the lunch
box will be delivered to their home and we will ask the
participants to take it as their dinner.
The subjects will cook their breakfast and dinner by
themselves and eat the proportion following the nutrition-
ist advices. They will take the pictures of each meal by an
iPhone provided by the research. A researcher will upload
the pictures weekly to our data management server for
further evaluation.
3. Exercise + diet group:
The AEx + LCh group will perform the same exercise
program and follow the same diet program as above-
mentioned for AEx and LCh groups.
4. Control and reference groups:
The control and reference groups will be advised to
maintain their level of physical activity and habitual
eating during the intervention. After intervention, we
will provide to the control group an opportunity to
participate in our planned exercise and diet interven-
tion for 3 months.
Primary and secondary outcomes
Primary outcomes:
1. Liver fat content
2. Serum metabolomics, level of glucose, insulin,
triglycerides and free fatty acids
3. Gut microbiota composition
The measurements of liver fat content, variables related
to glucose metabolism, triglycerides and free fatty acids
will be assessed at baseline and 6-month follow-up; gut
microbiota composition will be measured at baseline,
3-month and 6-month time points.
Secondary outcomes:
1. Questionnaires of behavioural characteristics, diet,
physical activity, health condition and medications
2. Anthropometry (height, body weight, body size
demission of different region of body)
3. Blood pressure
4. Body composition (fat mass, lean mass and bone
mass)
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minutes step tests)
6. Muscle strength (maximal isometric voluntary
contraction of the right grip, left elbow flexors and
left knee extensors)
7. Venous blood sample (total cholesterol,
HDL-cholesterol, LDL-cholesterol, apolipoproteins
A-I and B, lipoprotein(a), cholesterylester fatty acid
composition, hormones, cytokines and serum
metabonomics)
The secondary outcome measures will be assessed at
baseline, 3- and 6-month time points except for body
composition (fat mass, lean mass and bone mass) and
blood sample which will be performed at the baseline
and 6-month time points.
Measurements procedures
1. Screening:
The purpose of the screening is to verify the eligibility
of potential participants. The recruitment of participants
will be done at Yangpu District Health Care Service
Centres and the Department of Endocrinology, Shanghai
Shidong Hospital Shanghai, China. The potential sub-
jects will be selected from the outpatient pool of those
who have records of ultrasound for evaluation of liver
fat and fasting blood results for diagnosing diabetes from
2012 to 2013. Registered nurses from health care centers
will first contact the potential subjects and invite them
to a study information meeting. Detailed information of
the objectives of the study, its nature and constraints,
the anticipated risks and the expected benefits are given
by the investigating physician of endocrinology and pro-
fessor of sport medicine in the recruitment information
meetings. When the screening consent form has been
signed, patients will be asked to fill in a screening ques-
tionnaire to check their health and medication back-
ground as well as alcohol consumption, and to undergo
a glucose tolerance test (blood draw after overnight fast-
ing, followed by samples of 30 minutes and 2 hours after
the intake of 75 g of glucose).
2. First visit of the Run-in Trial:
The run-in trial consists of an 8-week period during
which the participants who are qualified in terms of the
screening questionnaire will complete all of the forms
and protocols required for successful entry to the 1-year
study. The purpose of the run-in trial is to identify and
exclude those individuals who cannot or will not fulfil
the requirements of the study. This should decrease the
dropout rate of the 1-year study. We anticipate thatapproximately 50% of potential participants will not
complete the run-in trial with sufficient detail or com-
pleteness to be entered in the study.
In the first visit of the Run-in Trial, those subjects
qualified by screening (subjects who have fasting glucose
level between 5.6 and 6.9 mmol/L or after 2-h intake of
glucose between 7.8 to 11.0 mmol/L are willing to partici-
pate in this study will be invited for further blood sample
collection. In addition, the pre-diabetes and healthy ref-
erence groups will undergo the same procedure. During
the first visit, the participants will receive an in-depth
explanation of the 1-year study and informed consent
for the intervention and follow-up study will be obtained
in writing.
3. Second visit of Run-in Trial:
At the second visit, a physician and a researcher will
examine all the results of the first visit to verify that the
subject meets the inclusion criteria. If a person is qualified
for participation in the study, he or she will be invited to
the laboratory at the Department of Sport Medicine,
Shanghai University of Sport for demographic, health
history and physical activity questionnaires, height, weight,
waist circumference, blood pressure, physical perform-
ance, body composition by DXA, as well as instructions
for fecal sample and 24 hours urine collections. They will
be also invited to have a magnetic resonance spectroscopy
(1H MRS) scan to evaluate whether they have NAFLD
(>5% liver fat content). The qualification of the partici-
pants will be established after this visit and randomization
will be performed.
4. Randomization visit:
When the qualified subjects are randomized, an infor-
mation meeting will be organized for each group. Detail of
the activities during intervention will be explained by a
principle investigator or a co-principle investigator. For
the AEx group, we will provide walking poles and teach
them how to use it. A heart rate monitor (M5 Suunto Oy,
Finland) will be provided during each exercise session to
monitory the intensity and duration of exercise. For the
LCh group, a dietary consultation will be organized to in-
struct subjects how to prepare their breakfast and dinner
and what we are going to provide them for lunch during
the intervention. In addition, we will provide a mobile
phone to each subject and teach them how to take pic-
tures of their breakfast and dinner. For the AEx + LCh
group, we will provide instructions as abovementioned
both for exercise and diet groups. For the control group
and both reference groups, we will emphasize the import-
ance of their participation in study and instruct them to
maintain their habits during the intervention. All groups
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activities and a step counter will be provided to them to
monitory their daily walking status.
5. Follow-up visits:
The purpose of the follow-up visits is to monitor the
compliance, enhance retention of the subject in the
study, and obtain information on factors that may affect
outcomes of the study. After the randomization visit, a
study coordinator will contact participants every month
to check their exercise records and update the exercise
program. The study coordinator will also give feedback
of their dietary intake on the basis of the images of meals
and snacks provided by the subjects themselves. The par-
ticipants will have follow-up visits to the laboratory of
Shanghai Sport University at months 3, 6, 12. Their height,
weight, food frequency questionnaire, physical activity
record, fitness tests, blood pressure, blood samples,
fecal samples, urine samples and changes in health sta-
tus will be checked at those time points. MRI and DXA
will be included in the follow-up visits for months 6
and 12.
Methods of measurements
Questionnaire, anthropometry and physical examinations
Background information regarding lifestyle, behavioural
and motivational characteristics as well as medical history
will be collected by questionnaires. Data gathered from
eligible subjects will then be used to describe the study
populations, and individual results will be used to screen
the changes and for monthly feedback.
Daily physical activity will be recorded through an activ-
ity diary (designed by the study) during the 6-month inter-
vention and 6-month after intervention. In addition, food
records will be collected 12 times to estimate the subject’s
energy intakes and intake of different nutrients during the
study for all groups. The collected information will be
evaluated by exercise and nutrition experts, and feedback
will be given by each individual’s family doctor.
Height will be determined using a wall-fixed measuring
device, and weight using a calibrated scale. Height and
weight will also be used to determine body mass index
(BMI, weight(kg)/(height(m))2. Blood pressure will be
measured after 5 min rest. A physician will examine the
physical conditions of subjects and ensure that subjects
meet the inclusion criteria.
Blood samples
Glucose tolerance tests will be performed after overnight
fasting, 30 minutes and 2 hours after the intake of 75 g
glucose for the assessment of serum insulin (chemilumine-
sent immunoassay) and glucose (automatic biochemistry
analyzer).Venous blood samples will be taken in standardized fast-
ing conditions at 7–8 a.m. Total cholesterol, high-density
lipoprotein (HDL), low-density lipoprotein (LDL), triglyc-
erides, apolipoproteins A-I and B, lipoprotein (a), glucose,
insulin, cholesterylester fatty acid composition, free fatty
acid profile and sex hormones will be measured from
serum sample by conventional methods. We will use
appropriate methods to measure a range of factors re-
lated to inflammation. ELISA or Western Blotting can
be used to assess serum samples for leptin, adiponectin,
resistin, tumor necrosis factor alpha (TNFα), C-reactive
protein (CRP), interleukin (IL-6), interleukin 1β (IL-1β),
interleukin-1 receptor antagonist (IL-1Ra), and angio-
tensinogen, the fibroblast growth factor 23 (FGF23),
Zn-metalloendopeptidase (PHEX), matrix extracellular
phosphoglycoprotein (MEPE), and cartilage oligomeric
matrix protein (COMP). Plasma samples will be used
to assess lipopolysaccharides (LPS) concentration by
Endosafe-MCS (Charles River laboratories, Lyon, France)
based on the Limulus amaebocyte Lysate (LAL) kinetic
chromogenic methodology that measures color inten-
sity directly related to the endotoxin concentration in a
sample.
Serum free fatty acid profile measurement will be per-
formed in order to define the different fractions and ra-
tio of saturated, mono-unsaturated and polyunsaturated
fatty acids. The obtained information is needed to esti-
mate certain de novo lipogenic enzymes activity by com-
paring the ratio of different precursors and end-products
fatty acid metabolism in the serum. The information is
also needed to evaluate how diet, physical exercise and
liver fat affect the concentrations of free fatty acids and
their ratios in the serum. Gas chromatography-mass
spectrometer will be used for the analysis.Fecal samples collection
The fecal samples (two samples per each time) will be
collected during the second day of the 3-day dietary re-
cords collection. Detailed sample collection and transpor-
tation instructions are given by a study nurse. The study
will provide to subjects the materials for sample collection
and transportation from home to health care centre which
including: 1 cool box, 2 plastic specimen jars (the cover of
the jar contains the spatula), plastic bag, 4 cold chargers
and plastic gloves. The subjects are advised to sample ap-
proximately 2–3 grams of feces by spatula attached to the
cover of the plastic specimen jar. Then put fecal samples
into the specimen jar and close it. The jars are stored in a
plastic bag with the cool box. After samples are collected,
the subjects will immediately deliver the samples to the
health care centre (mostly about 5–10 min walking dis-
tance). If the subjects are not able to deliver the sample by
themselves, the will call our research line and a personal
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jects home within 30 min to 1 hour.
Fecal samples are frozen after collection, stored
at −80°C, and the DNA will be extracted with a fully auto-
mated instrument using magnetic beads-based technology
(Genoextract, Hain Lifescience GmbH, Germany). Whole-
genome sequencing will be performed using Illumina
Hiseq 2000 system. In addition, fecal bacteria composition
will be analyzed with a method based on flow cytometry,
16S rRNA hybridization, and DNA-staining. Different bac-
terial indices will be calculated to evaluate the inter-
relationship of different bacterial species and how they are
associated with liver fat content [8]. Concentrations of
short chain fatty acids (SCFAs) will be determined in the
supernatant using an Agilent 6890 N gas chromatograph
with flame ionization detection and using ChemStation
software for data processing.
Urine sample collection
Twenty-four hours urine samples will be collected in the
morning after avoiding the first sample during the 2nd to
3rd day of the 3-days dietary records collection. The de-
tailed instruction on urine sample collection will be given
to the subject by a study nurse. Special sample collection
device will be provided to the subjects. The device allows
us to store small proportion of the total sample for whole
day including information of total volume of samples. The
sample will be stored at −80°C until analysis. The function
of kidney and the concentration of minerals will be
analysed.
Abdominal fat assessment
For abdominal fat assessment, axial T1-weighted dual-
echo (in-phase and out-of-phase) Volumetric Interpolated
Breath-hold Examination (VIBE) images will be obtained
of the entire abdominal area with a single breath-hold
using the following parameters: repetition time (TR)
4.36 ms, first echo time (TE1) 1.33 ms (out-of-phase) and
second echo time (TE2) 2.45 ms (in-phase), slice thickness
4.8 mm, voxel size 1.9×1.3×4.8 mm, distance factor 20%,
matrix 320 × 208, field of view (FoV) 40 cm, flip angle
(FA) 9 degrees and average acquisition time of 15 s. Areas
of abdominal subcutaneous, visceral and retroperitoneal
fat will be semi-automatically segmented using the OsiriX
software package (OsiriX Foundation, Geneva, Switzerland).
Measured volumes of each of the abdominal adipose tissue
compartments will be converted into tissue mass taking
into account slice thickness and an adipose tissue density
of 0.9196 g/ml [25].
Hepatic fat content assessment
Non-invasive measurement of hepatic fat content (HFC)
will be performed using single-voxel proton magnetic reson-
ance spectroscopy (1H MRS). The 1H MRS measurementswill be performed on a 3 T Siemens Magnetom Verio
scanner (Siemens Medical Solutions, Erlangen, Germany)
using the appropriate elements of the Body Matrix and
built-in spine coil as the receiving elements. A respiratory
(bellows) gated point-resolved spectroscopy (PRESS) se-
quence with the following parameters will be used: TR
3000 ms, TE 30.0 ms, number of averages 24 (for both
suppressed and unsuppressed water signals) and typical
acquisition time of 1 min 24 s. Obtained spectra will be
analysed using the Linear Combination of Model spec-
tra software suite which is generally considered to be
the gold standard for in-vivo spectroscopy analysis [26].
The fat and water spectrum signals will be corrected for
differences in T2 decay, molar concentrations of 1H nu-
clei in fat and water and HFC will be defined as fat in
relation to the total weigh of liver tissue, as previously
described [23].
Body composition
Dual-energy X-ray absorptiometry (DXA Prodigy, GE
Lunar Corp., Madison, WI USA with software version
13.60.033) will be used to estimate lean tissue mass (LM),
fat mass (FM) and bone mass (BM) of the whole body,
legs, arms, and trunk as well as android and gynoid re-
gions. All metal items will be removed from the partici-
pants to ensure the accuracy of the measurement.
Fitness test and heart rate
2 km walking test will be performed by walking 2 kilo-
metres as fast as possible on a flat surface [27]. The result
is recorded as a fitness index taking into account person’s
age, gender, height, weight, time taken to walk 2 kilo-
metres and the heart rate at the end of the test. There are
five fitness classes which can be used to compare result
with the fitness of others of the same age and gender or a
person’s own previous results and development between
the tests. The individual’s result will be used to set up their
own personalized exercise program.
The YMCA Step Test is a relatively low stress effort and
therefore can be used for unfit individuals [28]. Beat-by-
beat heart rate will be recorded continuously during 3
minutes exercise, and in a sitting posture at rest before
exercise, and 1 minute after exercise [28].
Muscle strength test
Maximal isometric voluntary contraction (MVC) of the
right hand grip strength, left elbow flexors and left leg
extensors will be measured in a sitting position with an
adjustable dynamometer chair (Good Strength). Subjects
will be encouraged to exert their maximal effort during
an isometric test for ~3 s. The MVC of the hand grip
strength, elbow flexors will be measured with the subject’s
forearm strapped at the wrist using Velcro straps with
elbow at 90° and the thumb in an upward position. Seat
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90° to the chest and the elbow is at the pivot point of the
apparatus. In the measurement of MVC of knee extensors,
the subject’s lower leg will be strapped at the distal end of
the lower leg using Velcro straps with knee at 120°. Seat
height will be adjusted to ensure that the hip will be at 90°
to the trunk and the knee will be at the pivot point of the
apparatus. The hip will be also strapped by Velcro straps
to limit its movement.Concomitant adherences and procedures
During the intervention, an exercise instructor will en-
sure that each individual has the right starting level and
will follow their progress during the entire trial. We will
organize the participants into groups according to their
time and places of residence. Exercising together as a
team will increase their compliance. A group leader of
each 10 subjects will be selected by participants to assist
the instructor to ensure a high participation rate. The
exercise instructor will be with the subjects at least three
times a week during the intervention. Group feedback
meetings will be arranged every 3 months during the
trial by an exercise specialist.
To ensure good compliance in diet intervention, we
provide a mobile phone to the subjects to allow them to
take photographs of their breakfast and dinner daily dur-
ing the study. The photos are downloaded by a researcher
weekly. The study nutritionist analyses dietary compos-
ition from the uploaded photos and gives feedback to each
participant monthly. In addition, food diary information is
also collected at the 3-month time point in order to give
more dietary suggestions to the subjects. A clinical nutri-
tionist will hold nutritional education meetings three
times for the diet and AEx + LCh groups during the inter-
vention period.
For the control and reference groups, we will keep in
contact with them via phone call monthly and question-
naire to check on their physical condition and lifestyle at
3 and 6 months follow-up during the intervention.Sample size estimation
The sample size calculation (drawing on previous litera-
ture) with an estimate of how many participants will be
needed for the primary outcome to be statistically, clinic-
ally and/or politically significant. For the specific primary
outcome of liver fat and microbiota, based on our plot
study, 34 subjects in each group would have 85% power
for mean comparison between the randomized groups for
the liver fat. We set the significance level at 0.05 and
allowed for 10 mean comparisons with the Bonferroni cor-
rection between the groups. Taking into account multi-
variable comparisons in the analysis, we increase our sim-
ple size to 50 in each group. We also taking into accountthe compliance and drop-out (15%), thus the total number
of subjects was estimated to meet each specific aim.
In addition, typical projection-based methods used to
analyze whole-genome data, such as Principal Component
or Partial Least Squares Regression, do not have statistical
inference methods. Thus, the corresponding methods for
sample size estimation are data-driven methods involving
latent variables. However, the large dimension and the
time series nature of our datasets provide a good oppor-
tunity for inferring associations between different mea-
surements. By using a systems biological approach we can
develop models based on path analysis, which compre-
hensively integrate data for analysis. With such models
we will be able to reveal the relationships between differ-
ent variables.Randomization methods
1. Randomization Process:
A computer program will be used for generating the
randomization assignment for this study by a statistician.
10 blocks of 20 randomization numbers will be generated
and sealed in an envelope and kept by the study coordin-
ator. On the basis of subjects’ enrolment time when 20
qualified subjects are reached, the study coordinator will
open one block to allocate subjects into one of the 4
groups (target 50 persons per group, see Figure 1):
1) Exercise group (AEx)
2) Diet group (LCh)
3) Exercise + Diet group (AEx + LCh)
4) Control group (Con)
In addition two references groups are not in
randomization:
5) Pre-diabetes without NAFLD (Ref1)
6) Healthy reference group (Ref2)
2. Blinding:
Since lifestyle intervention is not possible for subjects
to be blinded, we have designed the study in such way
that the tests and analyses will be blinded for investigators
during the study.
The study coordinator will be blinded from which
group the participants are signed in. The accuracy of
the randomization log is the responsibility of the study
coordinator.
Investigators will be blinded with respect to the ran-
domization assignment of each participant. The investi-
gators will remain blinded until the completion of the
study.
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All data collected by questionnaires will be entered into
database management software (Filemaker Pro version
10, FileMaker Inc. Santa Clara, CA, USA), double checked
by independent researchers, and exported to PASW statis-
tics version 20 (IBM Corporation, USA). If data is not
normally distributed, their natural logarithms will be
used for further analysis. Descriptive statistics will be
used to present the background and anthropometric
data at the baseline and follow-up assessments as mean
and 95% confidence interval (CI) unless otherwise stated.
An intention-to-treat (ITT) analysis will be performed
to compare the AEx, LCh and AEx + LCh groups to Con
group. The effects of the interventions will be assessed
using analysis of variance (ANCOVA) for repeated mea-
sures (treatment group × time) and baseline difference
as a covariate. If the significance of the group by time
interaction is p < 0.05, the effect will be localized utiliz-
ing Bonferroni for multiple comparisons. The level of
statistical significance chosen for the contrasts will be
p < 0.05. In addition to the ITT analysis, efficacy or ac-
tive treatment analysis will be done when the compli-
ance of the participation of the intervention is ≥60% of
the whole trial and for <60% not more than 3 months
continuously [ANCOVA for repeated measures (treatment
group × time) and baseline difference as a covariate.] The
percentage differences (0–6month) will be calculated
from duration between baseline and end point mea-
surements for each individual. The comparison of per-
centage changes in different groups will be performed
using ANCOVA (two factor interactions: compliance/
noncompliance × treatment group) controlled for the
baseline value using Bonferroni for multiple compari-
sons. If the significance of the overall group difference
is p < 0.05, then the effect will be localized by contrast
to the Con group. When the 95% CI does not include
zero, the difference is regarded as statistically significant at
α = 0.05.
Linear Pearson’s correlation, partial correlation, Kendall
Tau’s, and bivariate, logistic, and multivariate regression
analysis will be used for analysing relationships. In
addition, systems biology approaches will be used to de-
velop models which integrate the different types of data
and the high-throughput data measured in terms of gut
microbiota composition and fecal SCFAs content, as
well as LPSs and inflammation.
Ethical issues, research permits or information permit
applications
The current study will continue to adhere to all relevant
guidelines for good scientific and clinical practice. All
subjects in this study are volunteers. None of the mea-
surements are known to have any significant health risk.
The benefits and associated risks of the study will becarefully explained to the subjects and voluntary partici-
pation will be stressed. Informed consent will be ob-
tained from all subjects. The study physician will be
available during the laboratory tests. The study has been
approved by Ethics Committee of Shanghai Institute of
Nutrition, 06.01.2013, ref: 2013–003 and has registered
in International Standard Randomized Controlled Trial
Number Register (ISRCTN 42622771).
All data will be handled and archived confidentially.
All the samples will be coded by ID number without
personal information. All image scans and background
information will be electronically transferred and stored
in the specific database. The blood samples and fecal
samples will be stored at -80°C. If the analyses will be
performed outside the data collection site, the sample
transportation will be handled according to the relevant
safety standards. The duration of the sample storage is
generally 10 years. If the samples storage time are ex-
ceeds the permitted time, a new permit will be obtained
from both the subjects and the Ethical committee. If the
subjects are deceased, permission will be sought from
the relatives.
Discussion
NAFLD is a very prevalent and severe disease which can
lead to cirrhosis, liver carcinoma and death related to
liver morbidity [29]. Meanwhile, epidemiological studies
showed that 25% of patients with pre-diabetes progress
to type 2 diabetes in 5 years [30] and several prospective
studies even suggested that the rate may be even higher,
averaging 10-12% annually [31-33]. Recent studies have
reported novel mechanisms for the pathogenesis of
NAFLD and diabetes, especially involving the gut micro-
biota [34,35]. However, the studies that have suggested a
role of the gut microbiota in NAFLD and diabetes have
been mainly conducted in animal models [35,36]. In
addition, it is not clear whether NAFLD is due to im-
paired glucose metabolism or vice versa. There are very
few studies examining the link between gut microbiota
and the development of NAFLD in humans. Moreover,
the relationship between gut microbiota composition
and different nutritional status and physical activity has
been explored mainly in animal models, but not in
humans [36]. To the best of our knowledge, the AELC-
study is the first study that includes specific lifestyle
intervention attempting to modify patients’ diet and
physical activity, which are expected to change the gut
microbiota composition and therefore reduce the severity
of NAFLD and prevent diabetes.
We expect that both exercise and diet intervention will
induce favourable changes in gut microbiota composition
thus improving metabolic state, and further reducing
liver fat content and prevent development of diabetes.
We also anticipate that the combined exercise and diet
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ercise or diet alone. The further follow-up after inter-
vention of the study will serve as a pilot for future large
scale studies to evaluate how, in practice, exercise and
diet programmes can sustain their positive impacts on
health in these high risk populations.
From a clinical point of view, using lifestyle intervention
offers a novel approach for liver fat reduction and diabetes
prevention through modification of gut microbiota com-
position, and highlights the importance of incorporating
fitness assessment and prescription in the management of
patients with fatty liver disorders [21,22,37] and high risk
of diabetes [9]. However, the challenge is how to motivate
the inactive people who are at high risk for metabolic
disorders and who really need to escape from unhealthy
lifestyles, to start and, more importantly, to maintain
regular exercise. Therefore, this study will focus also on
implementing strategies to promote behaviour change
including regular contact and assessment with a health
care professional, self-monitoring, and personalization
of goals to change physical activity and unhealthy diet
behaviour.
This research using specific lifestyle interventions offers
a novel approach for liver fat reduction and diabetes inter-
vention via modification of the gut microbiota compos-
ition, and explores the importance of incorporating fitness
assessment and exercise in the management of patients
with pre-diabetes and fatty liver disorders. If our program
is shown to be effective, it will open new strategies to
combat these chronic diseases.Trial status
Participant recruitment started in January 2013. Baseline
measurement started in March 2013 for the first enrolled
group. Exercise, Diet, and Exercise plus diet interventions
started in March 2013. The recruitment of subjects is
continuing until June 2014.
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